Pharm@dvice
De berekende faillissementskans van Pharm@dvice over 12 maanden bedraagt 0,8% (laag). Het bedrijf is actief sinds 2010 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen. Er zijn geen verwerkte jaarrekeningcijfers beschikbaar; deze conclusie steunt uitsluitend op register- en Staatsbladgegevens.
| Actief | 15 jaar |
| Vestigingen | 1 |
| Publicaties | 1 |
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
| Boekjaar | Type | Neerlegging | Referentie |
|---|---|---|---|
| 31-12-2024 | volledig | 14-08-2025 | 2025-00376987 |
| 31-12-2023 | volledig | 08-05-2024 | 2024-00084784 |
| 31-12-2022 | volledig | 26-07-2023 | 2023-00280542 |
| 31-12-2021 | volledig | 14-06-2022 | 2022-20067642 |
| 31-12-2020 | volledig | 20-07-2021 | 2021-37500579 |
| 31-12-2019 | volledig | 15-07-2020 | 2020-30500428 |
| 31-12-2018 | volledig | 08-07-2019 | 2019-31200230 |
| 31-12-2017 | volledig | 12-07-2018 | 2018-32300498 |
| 31-12-2016 | volledig | 09-05-2017 | 2017-11700172 |
| 31-12-2015 | volledig | 09-05-2016 | 2016-11800022 |
| NACE primair | Detailhandel(47730) |
| Rechtsvorm | BV(610) |
| Oprichtingsdatum | 08-09-2010 |
| Status | Actief |
| Postcode | 4347 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 64423A0297/00T000 | Wallonië | 792 m² | 1 · 149 m² | 12,6 m · 4 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
11-01-2024 Inkoop van eigen aandelen
Technische details
{
"events": [
{
"kind": "vzw_capital_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "share_buyback",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "nominal",
"share_class": null,
"n_new_shares": 100,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Manon Deprez",
"firm_city": null,
"firm_name": null,
"office_city": "Tilleur",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2024-01-11",
"filing_date": "2024-01-09",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2024-01-09",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0829.109.874",
"name_full": "PHARMA DEHAYBE",
"legal_form": "SRL",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "org",
"name": "la SRL PVC INVEST",
"role": "commanditaire",
"n_shares": null,
"share_class": null
}
],
"share_classes_after": []
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamFR | Pharm@dvice |